MX377532B - Sales y formas sólidas de un antibiótico de monobactam. - Google Patents

Sales y formas sólidas de un antibiótico de monobactam.

Info

Publication number
MX377532B
MX377532B MX2018003592A MX2018003592A MX377532B MX 377532 B MX377532 B MX 377532B MX 2018003592 A MX2018003592 A MX 2018003592A MX 2018003592 A MX2018003592 A MX 2018003592A MX 377532 B MX377532 B MX 377532B
Authority
MX
Mexico
Prior art keywords
salts
solid forms
monobactam antibiotic
oxo
amino
Prior art date
Application number
MX2018003592A
Other languages
English (en)
Other versions
MX2018003592A (es
Inventor
Andreas Fisch
Anthony Casarez
Bernd Ulrich Riebesehl
Eric Aubin
Folkert Reck
Heinz Ernst Moser
Marc Schoenhentz
Michael Mutz
Mika Lindvall
Robert Lowell Simmons
Vijay Sethuraman
Zaixing Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2018003592A publication Critical patent/MX2018003592A/es
Publication of MX377532B publication Critical patent/MX377532B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención proporciona nuevas formas sólidas, sales y polimorfos del ácido 1- (((Z) - (1- (2-aminotiazol-4-il) -2-oxo-2 - (((3S, 4R) -2- ácido oxo-4 - ((2-oxooxazolidin-3-il) metil) -1-sulfoazetidin-3-il) amino) etiliden) amino) oxi) ciclopropanocarboxílico (al que se hace referencia en este documento como Compuesto X), composiciones farmacéuticas que los contienen, y procesos para su fabricación y uso en terapia.
MX2018003592A 2015-09-23 2016-09-20 Sales y formas sólidas de un antibiótico de monobactam. MX377532B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222430P 2015-09-23 2015-09-23
PCT/CN2016/099482 WO2017050218A1 (en) 2015-09-23 2016-09-20 Salts and solid forms of monobactam antibiotic

Publications (2)

Publication Number Publication Date
MX2018003592A MX2018003592A (es) 2018-06-18
MX377532B true MX377532B (es) 2025-03-10

Family

ID=58385723

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003592A MX377532B (es) 2015-09-23 2016-09-20 Sales y formas sólidas de un antibiótico de monobactam.

Country Status (26)

Country Link
US (1) US10919887B2 (es)
EP (1) EP3353175B1 (es)
JP (1) JP6837480B2 (es)
KR (1) KR102749337B1 (es)
CN (1) CN108137573B (es)
AU (1) AU2016327264B2 (es)
CA (1) CA2999794C (es)
CL (2) CL2018000745A1 (es)
CY (1) CY1123509T1 (es)
DK (1) DK3353175T3 (es)
EA (2) EA202092620A1 (es)
ES (1) ES2817537T3 (es)
HR (1) HRP20201423T1 (es)
HU (1) HUE050849T2 (es)
IL (1) IL258254B (es)
LT (1) LT3353175T (es)
MA (1) MA42946B1 (es)
MX (1) MX377532B (es)
PH (1) PH12018500653B1 (es)
PL (1) PL3353175T3 (es)
PT (1) PT3353175T (es)
RS (1) RS60805B1 (es)
RU (1) RU2754180C2 (es)
SI (1) SI3353175T1 (es)
SM (1) SMT202000480T1 (es)
WO (1) WO2017050218A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912656T3 (es) * 2017-08-02 2022-05-26 Novartis Ag Proceso para preparar ácido 1-(((Z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoacetidin-3-il)amino)etiliden)amino)oxi)ciclopropano carboxílico
EP3666829B1 (en) * 2017-08-16 2025-11-12 LG Chem, Ltd. Use of zif-based powder as white pigment
EP3706738A1 (en) * 2017-11-10 2020-09-16 Novartis AG Administration of monobactam for the treatment of urinary tract infection
JP7280273B2 (ja) * 2018-01-29 2023-05-23 メッドシャイン ディスカバリー インコーポレイテッド 細菌感染を治療するための単環β-ラクタム化合物
CN113227088B (zh) * 2018-12-18 2022-05-31 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
EP4046998B1 (en) * 2019-11-22 2024-02-28 Suzhou Erye Pharmaceutical Co., Ltd. Sulfonylurea ring substituted monocyclic beta-lactam antibiotics
CN114828850B (zh) 2019-12-19 2024-08-13 深圳嘉科生物科技有限公司 化合物在制药中的应用
CN113754651B (zh) 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN114728953B (zh) * 2020-08-06 2024-04-09 宁夏农林科学院 β-内酰胺类化合物,及其制备方法以及其作为抗菌素的应用
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
CN115304594B (zh) * 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196202A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Beta-lactam antibiotics (of azetidine-sulphonic acid type)
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
EP0048953B1 (en) 1980-09-29 1988-03-09 E.R. Squibb & Sons, Inc. Beta-lactam antibiotics
WO1982001873A1 (en) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4782147A (en) 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
AU564150B2 (en) * 1982-04-30 1987-08-06 Takeda Chemical Industries Ltd. 1-sulfo-2-azetidinone derivatives
HU189290B (en) 1982-05-31 1986-06-30 Banyu Pharmaceutical Co Ltd,Jp Process for preparing new 2-oxo-1-azetidine-sulphonic acid derivatives and pharmaceutically acceptable salts thereof, further pharmaceutical compositions containing such derivatives as active substances
EP0096297B1 (de) 1982-06-03 1988-06-15 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von 1-Sulfo-2-oxoazetidinderivaten
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd 2−オキソ−1−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
MX2011004636A (es) 2008-10-31 2011-06-20 Shionogi & Co Cefarosporinas que tienen un grupo catecol.
JP2012512863A (ja) 2008-12-19 2012-06-07 ファイザー・インク モノカルバム
DK2646436T3 (en) 2010-11-29 2015-06-29 Pfizer monobactams
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
WO2015103583A1 (en) 2014-01-06 2015-07-09 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
CN106164072B (zh) * 2014-03-24 2019-10-01 诺华股份有限公司 用于治疗细菌感染的单环内酰胺有机化合物

Also Published As

Publication number Publication date
AU2016327264B2 (en) 2019-06-27
WO2017050218A1 (en) 2017-03-30
CA2999794A1 (en) 2017-03-30
CY1123509T1 (el) 2022-03-24
RU2754180C2 (ru) 2021-08-30
US20180273522A1 (en) 2018-09-27
EP3353175A1 (en) 2018-08-01
PT3353175T (pt) 2020-09-10
RU2018114480A (ru) 2019-10-23
CN108137573A (zh) 2018-06-08
MA42946B1 (fr) 2020-10-28
US10919887B2 (en) 2021-02-16
JP2018528241A (ja) 2018-09-27
PL3353175T3 (pl) 2021-02-22
EP3353175A4 (en) 2019-06-26
PH12018500653A1 (en) 2018-10-01
PH12018500653B1 (en) 2022-05-04
MA42946A (fr) 2018-08-01
RS60805B1 (sr) 2020-10-30
KR102749337B1 (ko) 2025-01-03
SMT202000480T1 (it) 2020-11-10
SI3353175T1 (sl) 2020-11-30
KR20180054816A (ko) 2018-05-24
LT3353175T (lt) 2020-10-12
HUE050849T2 (hu) 2021-01-28
EP3353175B1 (en) 2020-08-12
IL258254B (en) 2021-02-28
HK1257271A1 (en) 2019-10-18
CL2018000745A1 (es) 2018-06-22
IL258254A (en) 2018-05-31
AU2016327264A1 (en) 2018-05-10
CN108137573B (zh) 2021-06-11
CL2019003324A1 (es) 2020-04-17
JP6837480B2 (ja) 2021-03-03
CA2999794C (en) 2023-08-15
EA037569B1 (ru) 2021-04-15
EA201890771A1 (ru) 2018-09-28
MX2018003592A (es) 2018-06-18
BR112018005805A2 (pt) 2018-10-16
DK3353175T3 (da) 2020-09-14
EA202092620A1 (ru) 2021-06-30
HRP20201423T1 (hr) 2020-12-11
ES2817537T3 (es) 2021-04-07
RU2018114480A3 (es) 2020-06-09

Similar Documents

Publication Publication Date Title
MX2018003592A (es) Sales y formas solidas de un antibiotico de monobactam.
BR112019004100A2 (pt) compostos de biarila úteis como imunomoduladores
CO2018004124A2 (es) Compuestos heterocíclicos
CL2017002650A1 (es) Compuestos novedosos
BR112017010354B8 (pt) Compostos de triazolopirimidina, seu uso, e composição farmacêutica
CO2017011484A2 (es) Inhibidores de bromodominio
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
MX364559B (es) Metodos de purificacion de cannabinoides, composiciones y kits de los mismos.
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
BR112016023558A2 (pt) compostos úteis como imunomoduladores
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
UY35467A (es) Compuestos orgánicos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
MX2019001011A (es) Compuestos farmaceuticos.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CO2019006687A2 (es) Polimorfos
MX2019007336A (es) Polimorfos.
MX2017007377A (es) Compuestos organicos.
CL2016000568A1 (es) Compuestos derivados de 2h-indazol-2-il-n-hidroxi-2-metilsulfonil-2-metil-butanamida sustituidos o sus sales; sus composiciones farmacéuticas que los contiene y su uso para la prevención y/o tratamiento de infecciones bacterianas gram-negativas.
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).

Legal Events

Date Code Title Description
FG Grant or registration